Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
Why the study?
Does carvedilol improve outcomes compared to metoprolol tartrate in patients with chronic heart failure, regardless of achieved heart rate, blood pressure, and beta-blocker dose?
Population
Patients with chronic heart failure
Comparison
Carvedilol at pre-defined target doses vs Metoprolol tartrate at pre-defined target doses
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
Carvedilol remains superior to metoprolol tartrate in HF independent of achieved dose, HR, or SBP; confirms agent-specific benefits beyond these parameters.
Structured PICO
Does carvedilol improve outcomes compared to metoprolol tartrate in patients with chronic heart failure, regardless of achieved heart rate, blood pressure, and beta-blocker dose?
P
Population
Patients with chronic heart failure
I
Intervention
Carvedilol at pre-defined target doses
C
Comparator
Metoprolol tartrate at pre-defined target doses
O
Outcome
Outcome (prognostic value)
The superiority of carvedilol over metoprolol tartrate in chronic heart failure is maintained regardless of the achieved heart rate, systolic blood pressure, or beta-blocker dose.
Cite This Study
Metra et al. (2005) studied this question.